Differential effect on TCR:CD3 stimulation of a 90‐kD glycoprotein (gp90/Mac‐2BP), a member of the scavenger receptor cysteine‐rich domain protein family

We studied the effects of a 90‐kD glycoprotein (gp90/Mac‐2BP) belonging to the scavenger receptor family, present in normal serum and at increased levels in inflammatory disease and cancer patients, on some T cell function parameters. Whereas the lymphocyte proliferative response to non‐specific mitogens such as phytohaemagglutinin (PHA) and concanavalin A (Con A), but not pokeweed mitogen (PWM), was strongly reduced, probably due to the lectin‐binding properties of gp90/Mac‐2BP, the response to T cell receptor (TCR) agonists such as superantigens and allogeneic cells was potentiated. When lymphocytes were stimulated with different anti‐TCR:CD3 MoAbs, both in soluble and solid‐phase form, gp90/Mac‐2BP was able to down‐regulate the proliferative response to anti‐CD3 MoAb, whereas the response to anti‐TCR αβ MoAb was enhanced. A similar differential effect was observed when a MoAb against CD5 (another member of the scavenger receptor superfamily) was added to anti‐CD3 or anti‐TCR‐stimulated cells; anti‐CD5 MoAb strongly down‐modulated the CD3‐mediated response, whereas its presence in culture was associated with potentiation of the response to TCR αβ agonists. gp90/Mac‐2BP was able per se to up‐regulate Ca2+ levels in freshly isolated lymphocytes; moreover, its presence in culture was associated with increased Ca2+ mobilization following stimulation with anti‐TCR αβ, but not anti‐CD3 MoAb. These data indicate that gp90/Mac‐2BP could be able to influence some immune responses, possibly through multiple homologous interactions with other members of the scavenger receptor family; moreover, our findings suggest that signalling through the different components of the TCR:CD3 complex may follow distinct activation pathways into the cells.

[1]  A. Ullrich,et al.  90K (Mac‐2 BP) in human milk , 1996, Clinical and experimental immunology.

[2]  A. Ullrich,et al.  Suppression of tumor growth in vivo by local and systemic 90K level increase. , 1995, Cancer research.

[3]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[4]  B. Haynes,et al.  Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells , 1995, The Journal of experimental medicine.

[5]  A. Ullrich,et al.  Effects of type‐I and ‐II interferons on 90K antigen expression in ovarian carcinoma cells , 1994, International journal of cancer.

[6]  M. Murgia,et al.  Cytosolic free calcium concentration in the mitogenic stimulation of T lymphocytes by anti-CD3 monoclonal antibodies. , 1994, Cell calcium.

[7]  A. Ullrich,et al.  The secreted tumor-associated antigen 90K is a potent immune stimulator. , 1994, The Journal of biological chemistry.

[8]  N. Tinari,et al.  Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). , 1994, Anticancer research.

[9]  Richard D. Cummings,et al.  Galectins: A family of animal β-galactoside-binding lectins , 1994, Cell.

[10]  P. Vassalli,et al.  Cloning and expression of a mouse macrophage cDNA coding for a membrane glycoprotein of the scavenger receptor cysteine-rich domain family. , 1994, The Journal of biological chemistry.

[11]  P. Sismondi,et al.  Prognostic value of a novel circulating serum 90K antigen in breast cancer. , 1994, British Journal of Cancer.

[12]  M. Krieger,et al.  The SRCR superfamily: a family reminiscent of the Ig superfamily. , 1994, Trends in biochemical sciences.

[13]  J. Goedert,et al.  A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. , 1993, AIDS research and human retroviruses.

[14]  N. Tinari,et al.  Prognostic value of a novel circulating serum 90K antigen in HIV‐infected haemophilia patients , 1993, British journal of haematology.

[15]  C. Janeway,et al.  TCR-CD4 and TCR-TCR interactions as distinctive mechanisms for the induction of increased intracellular calcium in T-cell signalling. , 1993, Journal of immunology.

[16]  I. Weissman,et al.  Cloning and characterization of cyclophilin C-associated protein: a candidate natural cellular ligand for cyclophilin C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Taylor,et al.  Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. , 1993, The Journal of biological chemistry.

[18]  N. Tinari,et al.  Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. , 1993, British Journal of Cancer.

[19]  M. Nussenzweig,et al.  Functional reconstitution of an immunoglobulin antigen receptor in T cells , 1992, The Journal of experimental medicine.

[20]  G. Schiavo,et al.  CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients. , 1992, Journal of immunology.

[21]  P. Linsley,et al.  The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins , 1991, The Journal of experimental medicine.

[22]  L. Chieco‐Bianchi,et al.  B-cell activation during HIV-1 infection. III. Down-regulating effect of mitogens. , 1991, AIDS.

[23]  M. Freeman,et al.  An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Newell,et al.  Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen , 1990, Nature.

[25]  M. Pabst,et al.  Removal of endotoxin from protein solutions by phase separation using Triton X-114. , 1990, Journal of immunological methods.

[26]  M. Zanetti,et al.  Human CD4 binds immunoglobulins. , 1990, Science.

[27]  S. Iacobelli,et al.  Predictive value of multiple tumor marker assays in second‐look procedures for ovarian cancer , 1989, Gynecologic oncology.

[28]  S. Weiner,et al.  The Mac-2 antigen is a galactose-specific lectin that binds IgE , 1989, The Journal of experimental medicine.

[29]  A. Alberti,et al.  HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. , 1989, Journal of immunology.

[30]  P. Marrack,et al.  Alpha beta T cell receptor and CD3 transduce different signals in immature T cells. Implications for selection and tolerance. , 1989, Journal of immunology.

[31]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[32]  P. Rabinovitch,et al.  Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. , 1986, Journal of immunology.

[33]  S. Iacobelli,et al.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. , 1986, Cancer research.

[34]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[35]  T. Springer,et al.  Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. , 1982, Journal of immunology.

[36]  O. Mayo Fixation of New Mutants , 1970, Nature.

[37]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.